Page results
-
Clinician researchers at UCLH and UCL are leading a major UK clinical trial to test whether proton beam therapy (PBT) can significantly improve survival for patients with mesothelioma, a rare and aggressive cancer of the lining of the lung.
-
UCLH is committed to not only treat patients’ illnesses but to provide an environment and an experience which contributes to patients’ general wellbeing.
-
“Vaccines do not kill, the virus does”: that was the message from local leaders from a variety of different faiths during an event at the newly opened vaccination centre at the Business Design Centre in Islington.
-
Mark Emberton joined the board as a non-executive director on 1 September 2022. He is Professor of Intervention Oncology within the Division of Surgery and Dean of the Faculty of Medical Science at University College London.
-
Two directors have joined the UCLH Board – Liz O’Hara, director of workforce and Laura Churchward, director of strategy.
-
UCLH doctor 1 of 10 international members elected to National Academy of Medicine
-
On Saturday 25 June 2022, UCLH partnered with North Middlesex University Hospital and Whittington Health to run a summer sickle cell event at Tottenham Hotspur Stadium for children and young people with sickle cell disorder.
-
3000 participants have been recruited to a clinical trial led by UCL and UCLH aimed at reducing the number of patients with breast cancer who are given chemotherapy unnecessarily.
-
UCLH has welcomed its 1000th patient to our proton beam therapy department, which opened in December 2021.
-
Ibrahim Abubakar is Vice Provost (Health) and Professor of Infectious Disease Epidemiology at UCL. He is a member of the Global Preparedness Monitoring Board, University College London NHS Trust Board, UCL Partners Board and the Board of Resolve to Save Lives.
